Management of hepatitis C infection in the era of direct-acting antiviral therapy

1st International Conference on Tropical Medicine and Infectious Diseases (ICTROMI) Faculty of Medicine Universitas Sumatera Utara

Zain, L.H.^1 ; Sungkar, T.^1

Division of Gastroenterology and Hepatology, Department of Internal Medicine, Faculty of Medicine, University of Sumatera, Utara, Indonesia^1

关键词: Antiviral therapy;    Antivirals;    Hepatitis C;    Interferon alphas;    Side effect;    Treatment duration;    Viral infections;    Viral proteins;   

Others  :  https://iopscience.iop.org/article/10.1088/1755-1315/125/1/012087/pdf
DOI  :  10.1088/1755-1315/125/1/012087

来源: IOP

【 摘 要 】

Hepatitis C viral infection globally affects millions of people and commonly results in debilitating complications and mortality. Initial mainstay therapy consisted of pegylated interferon α (pegIFNα) with additional ribavirin that showed unsatisfactory cure rate, common side effects and complicated dosing, contributing to high discontinuation rate. Over the last few years, newer antivirals have been extensively studied, that are Direct-Acting Antivirals (DAAs). Specifically targeting viral protein mainly during replication phase, DAAs showed greater cure rate (commonly measured as sustained virologic response), improved safety profile and shorter treatment duration compared to traditional interferon-ribavirin therapy. Current guidelines have also included Interferon-free, often ribavirin-free, DAAs combinations that suggest promising outcomes. The current review highlights development of rapidly growing hepatitis C treatment including DAAs recommendations.